Big day for Quartermaster! We've raised $140M, led by Insight Partners, to grow our maritime data network for commercial fleets.
Incredibly proud of our team, and grateful to the captains, crews and owners who've given us space on their mast. More than 650 vessels in 25 countries and counting.
This year showed how much the world depends on knowing what's happening on the ocean, and how little of it anyone can actually see. That's the gap we're here to close.
Thank you to Insight Partners, Overmatch Ventures, First Round Capital, QuietCapital, Steel Atlas, TMV, BoxGroup, Operator Partners, and Stifel Bank for backing us.
How do you build a platform that provides both developers and agents with a best-in-class integration experience? That's the question we've been partnering with the Google for Developers team to answer... We've got some thoughts 👇️
We're building out the Speakeasy AI control plane to make sure that agents' connections to enterprise systems, are secure, governed, and observable.
However connection starts with having the right artifacts in place for agents to consume. That's where we've started our partnership with the Google team.
We've collaborated with them to build three artifacts so agents and developers can share the same stable integration path:
1. Gemini GenAI SDKs → typed, regenerable clients so every language stays aligned with the API. Wrong SDK, and everything downstream is sand.
2. Gemini API CLI → a discoverable CLI that automatically detects agents and provides structured output optimized for agents with progressively discoverable commands.
3. Gemini Docs MCP → structured Gemini docs as an MCP servers agents can query at runtime, served through Speakeasy’s control plane. Context as an artifact, not a markdown crawl.
And perhaps the most exciting bit... everything we've done with the Google team is being Open Sourced!
Check out the comments for a link to the Github repo ⭐️
AI is becoming increasingly capable of generating biological hypotheses, therapeutic candidates and experimental designs. But generating ideas is advancing much faster than our ability to test what those ideas will do in human biology. Existing systems force a tradeoff: the most biologically relevant approaches are slow and expensive, while faster in vitro and computational systems often lack the fidelity needed to capture human response.
Today, we’re announcing $20M in seed financing led by Quiet Capital, with participation from Gradient, Haystack and Compound, to help close that gap.
Polyphron is building artificial human biology: a system that combines automated manufacturing of donor-diverse human tissue with AI models that learn from how those tissues change over time.
Our goal is to create a verification layer for AI-driven biology: models can make predictions, test them against living human tissue, learn from the resulting trajectories and continuously improve.
We’re starting with cardiac tissue, expanding across donors, and bringing liver online next.
Our long-term goal is to model human response before a clinical trial is run.
We are just getting started.
🚨Today, we’re announcing Thatch raised a $108M Series C at a $1B valuation.
But the bigger story is the idea we’re betting on 👇
Healthcare is the biggest purchase that you never really get to make.
For decades, employers have chosen one health plan for everyone. We think there’s a better model: give people a health budget and let them choose the insurance and care that actually fits their life.
Healthcare serves whoever controls the dollar. We believe more of that power should belong to the consumer.
The idea is catching on. In the last twelve months, our ARR has grown nearly 7x, and more than 5,000 employers now use Thatch.
Grateful to raise this round from incredible partners at The General Partnership, Index Ventures, General Catalyst, Andreessen Horowitz, as well as Scale Venture Partners, Avid Ventures, SemperVirens VC, Quiet Capital, and QuantumLight.
I’m especially excited to highlight ADP Ventures, Paychex, and Eli Lilly and Company as strategic investors. When companies this deeply embedded in how America runs payroll and pays for healthcare back an individual-first model, it’s a sign the shift is real.
More importantly, none of this happens without our team, or without the employers making a simple but significant bet: that their people know what their families need better than they ever could.
We’re building a healthcare system people love by changing how we fund it.
And we’re just getting started.
Today, we are incredibly excited to announce that we've signed a definitive agreement to be acquired by Alliant Insurance Services, the fourth-largest brokerage firm in the country.
Nava was founded to bring high-quality, affordable healthcare to every American, and we built HQ to get there. Connecting HR, employees, and the teams that serve them in one system instead of the emails and spreadsheets that used to stand in the way.
Now, we get to do that at scale. Alliant and Nava are coming together to build the leading AI-native brokerage and accelerate our mission. Alliant is moving their employee benefits business onto the Nava platform and joining us on the #FixHealthcare mission, while Nava's clients gain Alliant's global scale and deep consulting capabilities.
Together, we'll serve over 4.5 million lives. We can’t wait to build the future of benefits brokerage together.
Brandon Weber, Co-Founder & CEO at Nava, sat down with Kevin Overbey, President of Employee Benefits at Alliant, to talk about what's ahead.
Full announcement in the comments.
#FixHealthcare#EmployeeBenefits#AI
Congratulations Taalas! We are proud and grateful to have partnered with the exceptional Taalas team from the earliest days and in every round since. What they’ve accomplished in such a short period is remarkable. This union with AMD only accelerates their journey to radically rethink AI compute. And what comes next (very soon) will be even more special.
We're excited to announce that AMD has entered into a definitive agreement to acquire Taalas, a pioneer in specialized AI inference technology.
Taalas's differentiated technology and world-class engineering team will strengthen AMD's AI roadmap, helping deliver breakthrough inference performance and efficiency across a growing range of AI applications.
Together with AMD's full-stack AI platform, we'll continue giving customers the flexibility to deploy the right compute solution for every AI workload.
More on the news: https://bit.ly/4fXxbQI
The limiting factor in software engineering is no longer writing code. It's validating it. Every major shift in software development has required new infrastructure, and AI-driven engineering is no different. RWX is the dev cloud built specifically for that transition.
I’m excited to announce $12 million in Series A financing led by Hyde Park Venture Partners. Existing investor Quiet Capital participated in the round, alongside The O.H.I.O. Fund, R1 Capital, and DV, as well as angel investors including Theo Browne, Bryan Johnson, and Jenkins creator Kohsuke Kawaguchi.
I wrote more about our founding story and thesis on our blog:
https://lnkd.in/e6JJfXcd
Today we announce $11M in funding to turbocharge the parts industry.
The parts industry moves billions of dollars a day, and many of the decisions inside it are still made by feel. A pricing manager glances at a competitor and picks a number. A buyer reorders roughly what was ordered last time, because that's what the system shows. Inventory sits on the assumption that whatever's in the warehouse today is roughly what should be there, with no real sense of what's about to move or what's about to become dead stock. Multiply that across every SKU, every location, every day, across an entire industry, and you get an enormous, invisible leak, not from any one decision, but from the sheer number of decisions no system is helping anyone make.
We started Intropy because we'd watched this problem up close, and it stuck with us: an industry this large shouldn't still be running on gut instinct.
So we built the intelligence and automation layer to close that gap.
Judgment that used to take years to develop is now built into the AI. Work that used to bottleneck around one experienced person now runs across an entire team. Decisions that used to be made by feel are now made with data, and the people making them are freed up to do the parts of the job only people can do.
This round is led by Felix Capital, with new backing from Quiet Capital, and continued support from General Catalyst and firstminute capital. Investors who saw the same thing we did: an industry this overlooked, yet so critical to society, is exactly where AI should be pointed next.
We are hiring across London and New York. If this sounds like a problem you want to solve, apply at intropy.ai.
Today we're announcing a $120 million Series C led by Menlo Ventures , bringing Assort Health's total funding to $222 million and our valuation to $1.2 billion.
The number is a milestone. But it was never the point.
Growing up, I was a patient transport volunteer. I helped people physically get to appointments and navigate a healthcare system that often didn't make sense to them. For some, simply having someone there to help made all the difference.
Helping one patient get the care they needed was rewarding.
But it was one person at a time.
That experience has stayed with me. It's why Assort exists: to make exceptional healthcare accessible anytime, anywhere, for anyone, and to reach as many patients as possible.
This funding is fuel for that mission.
Every call, text, referral, form, appointment, and outreach creates context.
Without Assort, context gets lost.
Patients repeat themselves. Staff become the glue between systems that don't talk. Follow-ups slip. People fall through the cracks. Care gets delayed.
Not because healthcare lacks information.
Because it lacks continuity.
What started as an AI agent answering phone calls has grown into a platform that schedules appointments, manages referrals, completes intake, proactively reaches patients, and helps healthcare organizations run the operational work for every visit.
The part that matters most is that every interaction builds on the last.
We call this Patient Journey Memory: turning disconnected touchpoints into one continuous conversation, so patients don't have to start over every step.
Our brand film says it simply: Healthcare That Remembers.
With this funding, we'll reach far more patients, serve many more healthcare organizations, keep building the product, and bring exceptional people onto the team.
One full-circle detail: in the cofounder-dating questionnaire Jon Wang and I filled out before starting Assort, I wrote that building a company worth $100 million would be an incredible outcome. We've now passed that by more than 10x.
It's a surreal milestone, and a reminder that the problem and opportunity are far bigger than we thought.
None of this is ours alone. To the customers and partners who trusted us early, challenged our thinking, and shaped Assort: thank you. You took a chance on a young company, held us to a very high standard, and made us better than we could have become on our own.
To Jean-Paul (J.P.) Sanday and Matt Murphy from Menlo Ventures and all new and returning investors: thank you for believing in our team and our mission.
And to the Assort team: building AI systems in healthcare is hard. Building them in a way that patients trust and healthcare organizations rely on every day is even harder. Thank you for how much you care, how hard you push, and the standard you continue to set.
We're still early. There are more patients to reach and a lot to build. That's why we're excited.
Come help make healthcare remember every patient. We're hiring.
Today we raised a $120M Series C at a $1.2B valuation, led by Menlo Ventures.
We now have over $220M to become the standard for how healthcare providers transform the patient journey with AI.
As a medical student at UCSF, I watched patients fall through the cracks for reasons that had nothing to do with medicine.
Healthcare has spent decades improving clinical outcomes, yet patients were still repeating their story, navigating disconnected systems, and too often giving up before they got the care they needed.
I couldn't accept that patients spent more time on hold than with their doctors. It felt like one of the biggest unsolved problems in healthcare.
So I left to build Assort Health.
Our first chapter was learning how complex each practice's care protocols really are. It took us months to build a single agent.
That's why we built Synapse, our agentic model. It gets sharper with every edge case it sees, and with 190M+ patient interactions behind it, no one's model has seen more. That's what lets non-technical people build agents in weeks, even for the most complex workflows, with industry-leading automation rates.
This is how we grew revenue 20x in 15 months, as leading providers chose the one platform proven to handle the complexity of healthcare workflows at scale.
But this was always meant to be just the first chapter.
The first interaction isn't only where care begins. It's where patient context is created. Get that right, and every step after becomes easier.
Today we're a platform for the whole journey. Our AI agents answer calls, schedule appointments, manage referrals, complete intake, refill medications, reach patients proactively, and collect payments, all personalized to each patient.
Grateful to Jean-Paul (J.P.) Sanday, Matt Murphy and the team at Menlo Ventures for leading, and to Lightspeed, Felicis, First Round Capital, Chemistry, Quiet Capital, and Joe Montana for backing us again.
To the Assort team and my co-founder Jeffery L.: none of this happens without your relentless focus and care. Fired up to build Healthcare that Remembers alongside you. Still Day One.
